Clinical, Regulatory & Evidence

Clinical, Regulatory & Evidence is the scientific backbone of a pharma asset. This pillar covers clinical trial infrastructure, regulatory strategy, real-world evidence, and medical affairs execution from IND and first-in-human studies through approval, launch, and label expansion.

This is where most of a program's time, capital, and technical risk sit. Trial timelines determine how much patent runway a brand can monetize, a regulatory misstep can cost quarters or kill an asset, and weak evidence can limit payer adoption even after approval. Increasingly, the same evidence program must support regulators, HTA bodies, payers, clinicians, and medical affairs.

The landscape spans distinct service lines. Full-service CROs such as IQVIA, ICON, Parexel, Fortrea, and Thermo Fisher/PPD run large multi-phase programs. Specialty CROs such as Medpace, Precision for Medicine, and Worldwide Clinical Trials bring depth in oncology, rare disease, and cell and gene therapy. Regulatory consultancies advise on FDA and EMA strategy, submission authoring, and post-approval commitments. RWE vendors curate claims, EHR, registry, lab, and linked datasets for HEOR, safety, access, and label-expansion questions.

The structural issue for small sponsors is leverage. A large CRO running a biotech's only program can control timeline, cost, and attention, while RWE vendors vary sharply in data provenance, linkage quality, and methodological transparency. Medical affairs adds another constraint: the work must build credible scientific exchange without crossing into promotion.

Selection depends on which capability is strategic versus rentable. For trials, weigh full-service scale against specialty depth and inspect the actual delivery team, site relationships, and patient-finding plan. For RWE, start with whether the dataset fits the decision question. For regulatory and medical affairs, judge defensibility: can the vendor's work stand up to a regulator, payer, or key opinion leader?